Skip to main content

Table 1 Clinical studies on selenium and radiotherapy between 1987 and 2012

From: Updates on clinical studies of selenium supplementation in radiotherapy

Study no. Reference Site of research Number of patients Study design Type of cancer/disease Radiotherapy delivery method
1 Pothier et al. [17] USA n = 71 Observation of Se levels Upper gastrointestinal cancer Not mentioned
2 Antila et al. [18] Finland n = 24 Observation of Se levels Breast cancer Energy photons followed by 6–12 MeV electrons
3 Piccinini et al. [19] Italy n = 66 Observation of Se levels Breast cancer (n = 38), lung cancer (n = 28) Not mentioned
4 Rostkowska-Nadolska et al. [20] Poland n = 78 Observation of Se levels carcinoma of the larynx X-Ray therapy
5 Yadav et al. [21] India n = 30 Observation of Se levels Head and neck cancer Not mentioned
6 Last et al. [22] UK n = 100 Observation of Se levels Non-Hodgkin’s lymphoma Not mentioned
7 Fraunholz et al. [23] Germany n = 224 Observation of Se levels Breast cancer (n = 94); cervical csncer (n = 25); head and neck cancer (n = 23); lung cancer (n = 19); prostate (n = 13); other (n = 50) 6-MV and/or 25-MV photons generated by a linear accelerator
8 Franca et al. [24] Brazil n = 209 Observation of Se levels Breast cancer Not mentioned
9 Zeng YC et al. [25] China n = 95 Observation of Se levels Non-small cell lung cancer with brain metastases 6MV external beam radiotherapy
10 Eroglu C et al. [26] Turkey n = 47 Observation of Se levels Head and neck cancer Not mentioned
11 Pakdaman, [27] Germany n = 32 Se supplementation Brain tumor Not mentioned
12 Kiremidjian-Schumacher et al. [28] USA n = 33 supplemented (n = 17) placebo (n = 16) Se supplementation Head and neck cancer Not mentioned
13 Micke et al. [29] Germany n = 48 Se supplementation Secondary lymphedema a linear accelerator with 6-MeV photons or a 60Co treatment unit
14 Elango et al. [30] India n = 126 Se supplementation Oral cancer a tele-cobalt beam (Theratron-780-60Co; phoenix-60Co; Gammatron-60Co)
15 Muecke et al. [31] Germany n = 81 supplemented (n = 39) control group (n = 42) Se supplementation Cervical cancer (n = 11); uterine cancer (n = 70) 6- to 18-MV linear accelerator
16 Buntzel et al. [32] Germany n = 39 Se supplementation Head and neck cancer Not mentioned
    Total = 1303